You are here
PROTEOTECH, INC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Tau Protein Aggregation Inhibitors for Tauopathies
Amount: $2,271,931.00DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by brain amyloid plaques consisting of insoluble beta-amyloid protein (A?), and neurofibrillary tangles (NFTs) conta ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Identification of Novel Small Molecules as Tau Protein Aggregation Inhibitors for
Amount: $770,675.00DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by brain amyloid plaques consisting of insoluble beta-amyloid (A2) and tau protein containing neurofibrillary ta ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Systemic AA Amyloidosis Inhibitors
Amount: $1,330,460.00DESCRIPTION (provided by applicant): Systemic AA Amyloidosis is characterized by the accumulation of insoluble fibril deposits containing the AA amyloid protein in different organs throughout the body ...
SBIRPhase II2008Department of Health and Human Services National Institutes of Health -
Laminin-Derived Protein Fragments as Inhibitors of Alzheimer's Amyloidosis
Amount: $2,288,170.00DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, and judgment that gradually ...
SBIRPhase II2006Department of Health and Human Services National Institutes of Health -
Proteoglycans/Glycosaminoglycans in APP Transgenic Mice
Amount: $520,841.00DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorders characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional sta ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Systemic AA Amyloidosis Inhibitors
Amount: $264,984.00DESCRIPTION (provided by applicant): Systemic AA amyloidosis is characterized by the deposition and accumulation of insoluble fibrillar deposits containing the AA amyloid protein in a number of differ ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
INHIBITORS OF ALZHEIMER'S DISEASE AMYLOIDOSIS
Amount: $0.00DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional stab ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health -
Amyloid Inhibiting Agent for Treatment of Alzheimer's
Amount: $0.00Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgement and emotional stability that gradually leads to profou ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
Amyloid Inhibiting Agent for Treatment of Alzheimer's
Amount: $789,141.00Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgement and emotional stability that gradually leads to profou ...
SBIRPhase II2001Department of Health and Human Services National Institutes of Health -
Alzheimer's Amyloid Plaque Persistence In Vivo
Amount: $0.00DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgment ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health